Chemours (CC) EBIT (2014 - 2026)

Chemours has reported EBIT for 13 years, with the latest figure at -$213.0 million in Q2 2026.

• On a quarterly basis, EBIT fell 10.94% year-over-year to -$213.0 million in Q2 2026; TTM through Jun 2026 was -$111.0 million, a 88.14% decrease from a year earlier, with the FY2025 full-year figure at -$64.0 million, down 120.06% from the prior year.
• EBIT was -$213.0 million for Q2 2026 at Chemours, down from $26.0 million in the prior quarter.
• The five-year high for EBIT was $304.0 million in Q1 2022, with the low at -$396.0 million in Q2 2023.
• Average EBIT over 5 years is $33.2 million, with a median of $39.5 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: EBIT slumped 282.49% in 2023, then surged 1116.67% in 2024.
• Over 5 years, EBIT stood at -$9.0 million in 2022, then soared by 33.33% to -$6.0 million in 2023, then soared by 1116.67% to $61.0 million in 2024, then plunged by 108.2% to -$5.0 million in 2025, then tumbled by 4160.0% to -$213.0 million in 2026.
• The last three EBIT figures came in at -$213.0 million (Q2 2026), $26.0 million (Q1 2026), and -$5.0 million (Q4 2025), per Business Quant data.